EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular effects of endocrine hypertension: insights from primary aldosteronism, pheochromocytoma, and Cushing syndrome

Mehmet Murat Şahin, Macit Kalçık, Mucahit Yetim, Muhammet Cihat Çelik, Lütfü Bekar, Yusuf Karavelioğlu

Exploration of Endocrine and Metabolic Diseases · 2026

DOI: 10.37349/eemd.2026.101454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, 2026. Verfasst von Mehmet Murat Şahin und 5 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocrine hypertension (HT) includes a group of secondary hypertensive disorders caused by hormonal excess, primarily primary aldosteronism (PA), pheochromocytoma and paraganglioma (PPGL), and Cushing syndrome (CS). Although relatively uncommon, these conditions confer a disproportionately high cardiovascular risk that extends beyond blood pressure elevation. Aldosterone, catecholamines, and cortisol each induce myocardial fibrosis, oxidative stress, and endothelial dysfunction, leading to left ventricular hypertrophy (LVH), arrhythmias, and heart failure. In PA, chronic aldosterone excess activates mineralocorticoid receptors in cardiac and vascular tissues, promoting collagen deposition, diastolic dysfunction, and atrial fibrillation (AF) that may regress after adrenalectomy or pharmacologic blockade. PPGL causes episodic catecholamine surges resulting in β-adrenergic overstimulation, calcium overload, and microvascular ischemia, producing reversible or sometimes persistent catecholamine-induced cardiotoxicity. CS induces concentric hypertrophy, metabolic derangements, and vascular injury through prolonged glucocorticoid exposure, with cardiovascular recovery often incomplete after biochemical remission. Despite distinct hormonal origins, these disorders share convergent mechanisms, including fibroblast activation, mitochondrial injury, and maladaptive remodeling, that define endocrine cardiomyopathy. Early detection and targeted hormonal treatment can reverse much of the cardiac and vascular damage, whereas delayed recognition leads to irreversible fibrosis and persistent diastolic dysfunction. Recognition of these hormone-specific mechanisms is crucial for clinicians to anticipate, manage, and prevent these deleterious cardiovascular effects. Advances in molecular genetics, cardiac imaging, and biomarker research are improving our understanding of genotype-phenotype relationships and long-term reversibility of injury. Endocrine HT should therefore be recognized as a systemic cardiovascular disorder in which hormonal excess functions as a primary pathogenic driver; timely diagnosis and multidisciplinary care remain key to reducing morbidity and mortality.

Zitieren

APA

Şahin, M. M., Kalçık, M., Yetim, M., Çelik, M. C., Bekar, L., & Karavelioğlu, Y. (2026). Cardiovascular effects of endocrine hypertension: insights from primary aldosteronism, pheochromocytoma, and Cushing syndrome. Exploration of Endocrine and Metabolic Diseases. https://doi.org/10.37349/eemd.2026.101454

Vancouver

Şahin MM, Kalçık M, Yetim M, Çelik MC, Bekar L, Karavelioğlu Y. Cardiovascular effects of endocrine hypertension: insights from primary aldosteronism, pheochromocytoma, and Cushing syndrome. Exploration of Endocrine and Metabolic Diseases. 2026. doi:10.37349/eemd.2026.101454

BibTeX
@article{ahin2026,
  author = {Şahin, Mehmet Murat and Kalçık, Macit and Yetim, Mucahit and Çelik, Muhammet Cihat and Bekar, Lütfü and Karavelioğlu, Yusuf},
  title = {Cardiovascular effects of endocrine hypertension: insights from primary aldosteronism, pheochromocytoma, and Cushing syndrome},
  journal = {Exploration of Endocrine and Metabolic Diseases},
  year = {2026},
  doi = {10.37349/eemd.2026.101454}
}
Kostenlos starten →